Valeant Pharmaceuticals Reports 2013 Second Quarter Financial Results

LAVAL, Quebec, Aug. 7, 2013 /PRNewswire/ --

  • Total Revenue $1.1 billion; an increase of 41% over the prior year, excluding one-time items in 2012 second quarter
  • Product Sales $1.06 billion; an increase of 43% over the prior year
    • 4% organic growth (same store sales) for the Developed Markets segment, excluding the impact from Zovirax Ointment
    • 5% organic growth (same store sales) for Developed Markets segment, excluding the impact from Zovirax Franchise
    • 14% organic growth (same store sales) for the Emerging Markets segment
  • GAAP EPS $0.03; Cash EPS $1.34, an increase of 54% over the prior year, excluding one-time items in 2012 second quarter
  • GAAP Operating Cash Flow $305 million; Adjusted Operating Cash Flow $423 million; an increase of 61% over the prior year excluding one-time items in 2012 second quarter
  • Bausch + Lomb acquisition closed August 5, 2013 and Valeant expects to realize significantly more than $800 million in synergies
  • 2013 Guidance for Cash EPS raised to $6.00 to $6.20, from $5.55 to $5.85, and includes;
    • Negative impact of $0.11 from pre-closing interest expense and additional share count associated with the Bausch + Lomb financing
    • Negative impact of $0.06 from foreign exchange movement

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announces second quarter financial results for 2013.

"The continued outperformance of our businesses, which delivered strong financial results and organic growth despite the genericization of our largest product in April, demonstrates the value of a diversified portfolio," stated J. Michael Pearson, chairman and chief executive officer.  "We are particularly pleased with the performance of our Emerging Markets segment, which delivered organic growth of 14%."

"In addition to focusing on managing our inline businesses, we were also able to close the acquisition of Bausch + Lomb in a timely basis and complete the integration planning for the transaction," continued Pearson.  "These activities set the stage for what we expect will be a smooth transition over the coming weeks and months."

Valeant Second Quarter Financial Results

Valeant's total revenues were $1.1 billion, up 34% compared to the second quarter of 2012, and product revenues were $1.06 billion, up 43% versus the year-ago quarter.  Excluding a one-time milestone payment of $45 million received in the second quarter of 2012 from GlaxoSmithKline for the U.S. market launch of Potiga, total revenue increased 41% over the year-ago quarter.   

Valeant's Developed Markets revenue was $792 million, up 37% as compared to the second quarter of 2012. This increase was led by the contribution from acquired businesses including strong growth in key areas such as our aesthetics franchise, which delivered its best quarter ever and OraPharma, our oral health business that continues to deliver double digit growth, while legacy products such as CeraVe, our skin care dispensed product line, grew more than 50% over the prior year, in addition to strong increases in our topical acne portfolio.  Same store organic product sales growth for this segment declined 1% for the quarter due to the impact of the Zovirax ointment genericization, which occurred in April 2013.  Excluding this impact, Developed Markets delivered 4% organic growth. While the Zovirax cream formulation did not have direct generic competition, this presentation was also impacted by the generic entrant.  Excluding the impact from the entire Zovirax franchise on organic growth, the remaining products in the Developed Markets segment delivered 5% organic growth.

Valeant's Emerging Markets revenue was $304 million, up 26% as compared to the second quarter of 2012.  This segment continued to perform well with every geographic business unit delivering double digit product sales growth.  Total same store sales growth was 14% for the segment, particularly driven by continued strong growth in Poland, Russia, Brazil, Mexico, South East Asia and South Africa.  Total pro forma sales growth for this segment was 12%.

The Company reported net income of $11 million for the second quarter of 2013, or $0.03 per diluted share.  On a Cash EPS basis, adjusted income was $421 million, or $1.34 per diluted share.  Excluding the one-time milestone payment in the second quarter of 2012, Cash EPS increased 54% over the year-ago quarter.  It should be noted that the Cash EPS for the second quarter includes a negative impact of $0.01 due to increased common shares associated with the Bausch + Lomb financing and the negative impact of $0.01 due to unfavorable foreign exchange. 

GAAP cash flow from operations was $305 million in the second quarter of 2013, and adjusted cash flow from operations was $423 million. Excluding the one-time milestone payment in the second quarter of 2012, adjusted cash flow from operations increased 61% over the year-ago quarter. This outstanding growth in adjusted cash flow from operations was driven by growth across all our businesses, coupled by improvements to working capital.

The Company's cost of goods sold (COGS) was $283 million in the second quarter of 2013.  After backing out the fair value adjustment to inventory, amortization expense and other items related to acquisitions, COGS represented 23% of product sales, a decrease of one percentage point as compared to the second quarter of 2012 due to a favorable product mix, global plant consolidations and other initiatives.   

Selling, General and Administrative expenses were $257 million in the second quarter of 2013 which includes a $17.1 million step-up in stock based compensation expenses and the modification of certain director equity awards which gave the Company a one-time right to settle these awards in cash.  The Company elected to cash settle a portion of these awards and the resulting net economic impact was the same as a share repurchase by the Company.  Excluding these expenses, SG&A was approximately 22% of revenue.  Research and Development expenses were $24 million in the second quarter of 2013, or approximately 2% of revenue.

Bausch + Lomb Transaction

On August 5, 2013, Valeant completed its acquisition of Bausch + Lomb.  To finance the transaction and add to our liquidity, Valeant raised $9.6 billion by issuing 27.1 million common shares, $3.2 billion in senior unsecured notes and $4.1 billion in senior secured credit facilities.  We expect to realize significantly more than $800 million of cost synergies from the combined Company, with a run rate north of $500 million by year-end 2013 and a run rate significantly more than $800 million by year-end 2014.  

2013 Guidance

The Company is updating its previous Cash EPS guidance and is now targeting Cash EPS of $6.00 to $6.20 in 2013, which includes the negative impact from the Bausch + Lomb pre-closing interest expense and additional share count of $0.11, and the negative impact of $0.06 from foreign exchange movement, up from prior guidance of $5.55 to $5.85.  Cash EPS expectations for the third and fourth quarters of 2013 are $1.33 to $1.43 and $2.03 to $2.13, respectively. In addition to the $0.01 negative impact that occurred in the second quarter from Bausch + Lomb pre-closing interest expense and additional share count, this new guidance also includes an additional $0.10 impact in the third quarter. This guidance includes a negative $0.05 in the second half of 2013 related to unfavorable foreign exchange in addition to the negative impact of $0.01 realized in the second quarter.  Total revenue for 2013 is expected to be in the range of $5.8 billion and $6.2 billion.  We will update our adjusted cash flow from operations expectations at the appropriate time.

Conference Call and Webcast Information

The Company will host a conference call and a live Internet webcast along with a slide presentation today at 8:00 a.m. ET (5:00 a.m. PT), August 7, 2013 to discuss its second quarter financial results for 2013. The dial-in number to participate on this call is (877) 876-8393 confirmation code 17202469. International callers should dial (973) 200-3961, confirmation code 17202469. A replay will be available approximately two hours following the conclusion of the conference call through August 14, 2013 and can be accessed by dialing (855) 859-2056, or (404) 537-3406, confirmation code 17202469. The live webcast of the conference call may be accessed through the investor relations section of the Company's corporate website at www.valeant.com.

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

Forward-looking Statements

This press release may contain forward-looking statements, including, but not limited to, statements regarding the amount and timing of synergies, our expected performance for 2013, including 2013 guidance with respect to Cash EPS and total revenue.  Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in Valeant's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof.  Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

Non-GAAP Information 

To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the company uses non-GAAP financial measures that exclude certain items, such as amortization of inventory step-up, amortization of alliance product assets & pp&e step up, stock-based compensation step-up, contingent consideration fair value adjustments, restructuring, acquisition-related and other costs, in-process research and development ("IPR&D"), legal settlements outside the ordinary course of business, the impact of currency fluctuations, amortization and other non-cash charges, amortization and write-down of deferred financing costs, debt discounts and ASC 470-20 (FSP APB 14-1) interest, loss on extinguishment of debt, (gain) loss on assets held for sale/impairment, net, (gain) loss on investments, net, and adjusts tax expense to cash taxes. Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results and evaluating current performance. By disclosing non-GAAP financial measures, management intends to provide investors with a meaningful, consistent comparison of the company's core operating results and trends for the periods presented. Non-GAAP financial measures are not prepared in accordance with GAAP.  Therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.      

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com

Financial Tables follow.





Valeant Pharmaceuticals International, Inc.

 Table 1 

Condensed Consolidated Statements of Income (Loss)


For the Three and Six Months Ended June 30, 2013 and 2012











Three Months Ended


Six Months Ended


June 30,


June 30,

(In thousands, except per share data)

2013


2012


2013


2012









Product sales

$ 1,063,513


$ 742,972


$ 2,102,380


$ 1,493,852

Alliance and royalty

13,922


56,869


23,180


136,100

Service and other

18,327


20,249


38,557


46,241

Total revenues

1,095,762


820,090


2,164,117


1,676,193









Cost of goods sold (exclusive of amortization of intangible assets shown separately below)

283,183


192,928


568,087


417,124

Cost of services

14,026


16,839


28,977


35,659

Cost of alliances

433


-


911


68,820

Selling, general and administrative ("SG&A")

257,373


185,440


499,272


362,726

Research and development

24,469


17,711


48,264


39,717

Acquisition-related contingent consideration

3,669


7,729


1,484


17,568

In-process research and development impairments and other charges

4,830


4,568


4,830


4,568

Legal settlements and related fees

1,124


53,624


5,572


56,779

Restructuring, acquisition-related and other costs

61,544


43,871


118,428


113,713

Amortization of intangible assets

303,598


210,570


629,773


411,213


954,249


733,280


1,905,598


1,527,887

Operating income (loss)

141,513


86,810


258,519


148,306









Interest expense, net

(175,739)


(99,594)


(329,458)


(200,496)

Gain (loss) on extinguishment of debt

-


-


(21,379)


(133)

Gain (loss) on investments, net

3,963


(35)


5,822


2,024

Foreign exchange and other

(10,082)


(4,238)


(8,643)


20,061









Income (loss) before (recovery of) provision for income taxes

(40,345)


(17,057)


(95,139)


(30,238)









(Recovery of) provision for income taxes

(51,211)


4,550


(78,475)


4,290









Net income (loss)

$      10,866


$  (21,607)


$    (16,664)


$    (34,528)









Earnings per share:
















Basic:








Net income (loss)

$          0.04


$      (0.07)


$        (0.05)


$        (0.11)

Shares used in per share computation

308,153


304,816


307,677


306,296









Diluted:








Net income (loss)

$          0.03


$      (0.07)


$        (0.05)


$        (0.11)

Shares used in per share computation

314,447


304,816


307,677


306,296





Valeant Pharmaceuticals International, Inc.

 Table 2 

Reconciliation of GAAP EPS to Cash EPS 


For the Three and Six Months Ended June 30, 2013 and 2012



















Three Months Ended


Six Months Ended


June 30,


June 30,

(In thousands, except per share data)

2013


2012


2013


2012









Net income (loss)

$   10,866


$  (21,607)


$  (16,664)


$  (34,528)









Non-GAAP adjustments(a):








Inventory step-up (b)

26,518


10,361


69,759


43,392

Alliance product assets & pp&e step-up/down(c)

413


313


551


51,034

Stock-based compensation (d)

17,134


7,274


16,854


17,702

Acquisition-related contingent consideration(e)

3,669


7,729


1,484


17,568

In-process research and development impairments and other charges (f)

4,830


4,568


4,830


4,568

Legal settlements and related fees(g)

1,124


53,624


5,572


56,779

Restructuring, acquisition-related and other costs(h)

61,544


43,871


118,428


113,713

Amortization and other non-GAAP charges(i)

316,097


213,652


652,872


418,855


431,329


341,392


870,350


723,611

Amortization of deferred financing costs, debt discounts and ASC 470-20 (FSP APB 14-1) interest(j)

33,279


(395)


42,926


5,355

(Gain) loss on extinguishment of debt

-


-


21,379


133

(Gain) loss on disposal of fixed assets and assets held for sale/impairment, net

-


1,002


-


1,002

Foreign exchange and other (k)

8,304


-


8,304


-

Tax(l)

(63,220)


(5,850)


(100,575)


(20,709)

Total adjustments

409,692


336,149


842,384


709,392









Adjusted Net income

$ 420,558


$ 314,542


$ 825,720


$ 674,864









GAAP earnings (loss) per share - diluted

$       0.03


$      (0.07)


$      (0.05)


$      (0.11)









Cash earnings per share - diluted

$       1.34


$       1.01


$       2.63


$       2.15









Cash earnings per share excluding one-time items - diluted

$       1.34


$       0.87


$       2.63


$       1.78









Shares used in diluted per share calculation - Cash earnings per share

314,447


312,631


314,118


314,514

















(a) See footnote (a) to Table 2a and Table 2b.





(b) See footnote (b) to Table 2a and Table 2b.







(c) See footnote (d) to Table 2b.







(d) See footnote (d) to Table 2a and (e) to Table 2b.







(e) See footnote (f) to Table 2a and (g) to Table 2b.







(f) See footnote (g) to Table 2a and (h) to Table 2b.







(g) See footnote (h) to Table 2a and (i) to Table 2b.







(h) See footnote (i)(j) to Table 2a and (j)(k) to Table 2b.







(i) See footnote (c)(e) to Table 2a and (c)(f) Table 2b.







(j) See footnote (k) to Table 2a and (l) to Table 2b.







(k) See footnote (l) to Table 2a and (m) to Table 2b.







(l) See footnote (m) to Table 2a and (n) to Table 2b.













Valeant Pharmaceuticals International, Inc.

 Table 2a 


Reconciliation of GAAP EPS to Cash EPS



For the Three Months Ended June 30, 2013 and 2012











Non-GAAP Adjustments(a) for




Three Months Ended




June 30,


(In thousands, except per share data)


2013


2012








Product sales


$             -


$                 -


Alliance and royalty


-


-


Service and other


-


-


Total revenues


-


-








Cost of goods sold (exclusive of amortization of intangible assets shown separately below)


(38,960)

(b)(c) 

(13,984)

(b)(c) 

Cost of services


-


-


Cost of alliances


-


-


Selling, general and administrative ("SG&A")


(17,604)

(d) 

(8,048)

(d)(e) 

Research and development


-


-


Acquisition-related contingent consideration


(3,669)

(f) 

(7,729)

(f) 

In-process research and development impairments and other charges


(4,830)

(g) 

(4,568)

(g) 

Legal settlements and related fees


(1,124)

(h) 

(53,624)

(h) 

Restructuring, acquisition-related and other costs


(61,544)

(i) 

(43,871)

(j) 

Amortization of intangible assets


(303,598)


(210,570)




(431,329)


(342,394)


Operating income (loss)


431,329


342,394








Interest expense, net


33,279

(k) 

(395)

(k) 

Gain (loss) on extinguishment of debt


-


-


Foreign exchange and other


8,304

(l) 

-








Income (loss) before (recovery of) provision for income taxes


472,912


341,999








(Recovery of) provision for income taxes


63,220

(m) 

5,850

(m) 







Total Adjustments to Net income (loss)


$   409,692


$       336,149








Earnings per share:












Diluted:






Total Adjustments to Net income (loss)


$         1.30


$             1.08


Shares used in per share computation


314,447


312,631














(a) To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the company uses non-GAAP financial measures that exclude certain items, such as amortization of inventory step-up, amortization of alliance product assets & pp&e step up, stock-based compensation step-up, contingent consideration fair value adjustments, restructuring, acquisition-related and other costs, in-process research and development ("IPR&D"), legal settlements outside the ordinary course of business, the impact of currency fluctuations, amortization and other non-cash charges, amortization and write-down of deferred financing costs, debt discounts and ASC 470-20 (FSP APB 14-1) interest, loss on extinguishment of debt, (gain) loss on assets held for sale/impairment, net, (gain) loss on investments, net, and adjusts tax expense to cash taxes. 


Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results and evaluating current performance. By disclosing non-GAAP financial measures, management intends to provide investors with a meaningful, consistent comparison of the company's core operating results and trends for the periods presented. Non-GAAP financial measures are not prepared in accordance with GAAP.  Therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. 


(b) ASC 805, accounting for business combinations requires an inventory fair value step-up whose total impact for the three months ended June 30, 2013 is $26.5 million primarily relating to the acquisition of Medicis Pharmaceutical Corporation on December 11, 2012.  For the three months ended June 30, 2012 the impact of inventory fair value step-up is $10.4 million primarily relating to the acquisitions of iNova on December 21, 2011 and Afexa Life Sciences on October 17, 2011.


(c) For the three months ended June 30, 2013 and 2012 cost of goods include costs associated with integration related tech transfers, $10.7 million and $3.0 million, respectively.  For the three months ended June 30, 2013 cost of goods include amortization of a BMS fair value inventory adjustment of $1.4 million.


(d)  For the three months ended June 30, 2013 and 2012 SG&A primarily includes $17.1 million and $7.3 million of stock-based compensation, respectively, which reflects the one time modification and cash settlement of certain board of directors equity instruments and the amortization of the fair value step-up increment resulting from the merger of Legacy Valeant into Legacy Biovail.


(e) SG&A includes $1.0 million loss on assets held for sale/impairment for the three months ended June 30, 2012.


(f) Net expenses from the changes in acquisition-related contingent consideration for the three months ended June 30, 2013 and 2012 of $3.7 million and $7.7 million, respectively.


(g) In-process research and development impairments and other charges for the three months ended June 30, 2013 of $4.8 million relates to impairment charges for IPR&D assets.  In-process research and development impairments and other charges for the three months ended June 30, 2012 of $4.6 million primarily relates to the termination of an IPR&D program acquired from Ortho Dermatologics.


(h)  For the three months ended June 30, 2013 and 2012 legal settlement costs of $1.1 million and $53.6 million, respectively, relate to settlements and associated legal fees of patent-related and anti-trust litigations.


(i) Restructuring, acquisition-related and other costs of $61.5 million primarily represent costs related to the acquisition of Medicis Pharmaceutical Corporation, Obagi Medical Products, Inc. and other Valeant restructuring and integration initiatives.   These include $25.5 million related to integration consulting, duplicative labor, transition services, and other, $11.6 million related to employee severance costs, $7.9 million related to acquisition costs, $5.1 million related to facility closure costs, $4.6 million related to other, $3.5 million of other non-cash charges, $2.2 million stock-based compensation, and $1.1 million related to non-personnel manufacturing integration costs.


(j) Restructuring, acquisition-related and other costs of $43.9 million represent costs related to the merger of Legacy Valeant into Legacy Biovail and the acquisitions of Afexa Life Sciences, iNova, Dermik, Sanitas, Ortho Dermatologics, PharmaSwiss SA, Probiotica, Eyetech, Pedinol, University Medical and Gerot Lannach.  These include $13.9 million related to acquisition costs, $12.2 million related to employee severance costs, $8.4 million related to integration consulting, duplicative labor, transition services, and other, $5.1 million related to facility closure costs, $2.3 million related to non-personnel manufacturing integration costs and $2.0 million related to other.


(k) Non cash interest expense associated with amortization and write-down of deferred financing costs and debt discounts for the three months ended June 30, 2013 of $33.3 million.  For the three months ended June 30, 2012 non cash interest expense associated with amortization and write-down of deferred financing costs, debt discounts and ASC 470-20 (FSP APB 14-1) interest is offset by an adjustment to deferred financing costs.


(l) Unrealized foreign exchange on intercompany financing arrangements, $8.3 million.


(m) Total tax effect of non-GAAP pre-tax adjustments, resolution of uncertain tax positions and change in valuation allowance associated with deferred tax asset.







Valeant Pharmaceuticals International, Inc.

 Table 2b 


Reconciliation of GAAP EPS to Cash EPS 



For the Six Months Ended June 30, 2013 and 2012











Non-GAAP Adjustments(a) for




Six Months Ended




June 30,


(In thousands, except per share data)


2013


2012








Product sales


$             -


$                 -


Alliance and royalty


-


-


Service and other


-


-


Total revenues


-


-








Cost of goods sold (exclusive of amortization of intangible assets shown separately below)


(92,949)

(b)(c) 

(50,405)

(b)(c) 

Cost of services


-


-


Cost of alliances


-


(50,958)

(d) 

Selling, general and administrative ("SG&A")


(17,314)

(e) 

(19,409)

(e)(f) 

Research and development


-


-


Acquisition-related contingent consideration


(1,484)

(g) 

(17,568)

(g) 

In-process research and development impairments and other charges


(4,830)

(h) 

(4,568)

(h) 

Legal settlements and related fees


(5,572)

(i) 

(56,779)

(i) 

Restructuring, acquisition-related and other costs


(118,428)

(j) 

(113,713)

(k) 

Amortization of intangible assets


(629,773)


(411,213)




(870,350)


(724,613)


Operating income (loss)


870,350


724,613








Interest expense, net


42,926

(l) 

5,355

(l) 

Gain (loss) on extinguishment of debt


21,379


133


Foreign exchange and other


8,304

(m) 

-








Income (loss) before (recovery of) provision for income taxes


942,959


730,101








(Recovery of) provision for income taxes


100,575

(n) 

20,709

(n) 







Total Adjustments to Net income (loss)


$   842,384


$        709,392








Earnings per share:












Diluted:






Total Adjustments to Net income (loss)


$         2.68


$              2.26


Shares used in per share computation


314,118


314,514














(a) See footnote (a) to Table 2a.


(b) ASC 805, accounting for business combinations requires an inventory fair value step-up whose total impact for the six months ended June 30, 2013 is $69.8 million primarily relating to the acquisition of Medicis Pharmaceutical Corporation on December 11, 2012.  For the six months ended June 30, 2012 the impact of inventory fair value step-up is $43.4 million primarily relating to the acquisitions of Dermik on December 16, 2011, iNova on December 21, 2011 and Afexa Life Sciences on October 17, 2011.




(c) For the six months ended June 30, 2013 and 2012 cost of goods include costs associated with integration related tech transfers, $18.1 million and $4.5 million, respectively.  For the six months ended June 30, 2013 cost of goods include amortization of a BMS fair value inventory adjustment of $3.5 million.




(d) Cost of alliances represents the divestiture of 5-FU and IDP-111 resulting from the acquisition of Dermik, $50.9 million for the six months ended June 30, 2012. 




(e)  For the six months ended June 30, 2013 and 2012 SG&A primarily includes $16.9 million and $17.7 million of stock-based compensation, respectively, which reflects the one time modification and cash settlement of certain board of directors equity instruments and the amortization of the fair value step-up increment resulting from the merger of Legacy Valeant into Legacy Biovail.




(f) SG&A includes $1.0 million loss on assets held for sale/impairment for the six months ended June 30, 2012.




(g) Net expenses from the changes in acquisition-related contingent consideration for the six months ended June 30, 2013 and 2012 of $1.5 million and $17.6 million, respectively.




(h) In-process research and development impairments and other charges for the six months ended June 30, 2013 of $4.8 million relates to impairment charges for IPR&D assets.  In-process research and development impairments and other charges for the six months ended June 30, 2012 of $4.6 million primarily relates to the termination of an IPR&D program acquired from Ortho Dermatologics.




(i)  For the six months ended June 30, 2013 and 2012 legal settlement costs of $5.6 million and $56.8 million, respectively, relate to settlements and associated legal fees of patent-related and anti-trust litigations.




(j) Restructuring, acquisition-related and other costs of $118.4 million primarily represent costs related to the acquisition of Medicis Pharmaceutical Corporation, Obagi Medical Products, Inc. and other Valeant restructuring and integration initiatives.   These include $49.9 million related to integration consulting, duplicative labor, transition services, and other, $27.4 million related to employee severance costs, $15.8 million related to acquisition costs, $9.3 million related to facility closure costs, $7.5 million related to other, $3.5 million of other non-cash charges, $2.2 million stock-based compensation, and $2.8 million related to non-personnel manufacturing integration costs.




(k) Restructuring, acquisition-related and other costs of $113.7 million represent costs related to the merger of Legacy Valeant into Legacy Biovail and the acquisitions of Afexa Life Sciences, iNova, Dermik, Sanitas, Ortho Dermatologics, PharmaSwiss SA, Probiotica, Eyetech, Pedinol, University Medical and Gerot Lannach.   These include $31.9 million related to employee severance costs, $23.7 million related to facility closure costs, $21.4 million related to acquisition costs, $21.4 million related to integration consulting, duplicative labor, transition services, and other, $11.2 million related to other, and $4.1 million related to non-personnel manufacturing integration costs.




(l) Non cash interest expense associated with amortization and write-down of deferred financing costs, debt discounts and ASC 470-20 (FSP APB 14-1) interest totals for the six months ended June 30, 2013 and 2012 of $42.9 million and $5.4 million, respectively.




(m) Unrealized foreign exchange on intercompany financing arrangements, $8.3 million.




(n) Total tax effect of non-GAAP pre-tax adjustments, resolution of uncertain tax positions and change in valuation allowance associated with deferred tax asset.














Valeant Pharmaceuticals International, Inc.





Table 3 

Statement of Revenues - by Segment






For the Three and Six Months Ended June 30, 2013 and 2012






(In thousands)







 Three Months Ended 


June 30,

Revenues(a)(b)

2013

GAAP


2012

GAAP


%   Change


2013 currency impact


2013 excluding currency impact

 non-GAAP


%   Change

    U.S. Promoted

$    487,090


$    256,983


90%


$        -


$    487,090


90%

    U.S. Neurology & Other

163,405


192,644


-15%


-


163,405


-15%

    Canada/Australia

141,330


128,360


10%


2,148


143,478


12%

Developed Markets

791,825


577,987


37%


2,148


793,973


37%

    Emerging Markets-Central/Eastern Europe

186,377


143,805


30%


(5,381)


180,996


26%

    Emerging Markets-Latin America

89,142


73,414


21%


(2,178)


86,964


18%

    Emerging Markets-Southeast Asia/Africa

28,418


24,884


14%


1,985


30,403


22%

Emerging Markets

303,937


242,103


26%


(5,574)


298,363


23%

Total Revenues

$ 1,095,762


$    820,090


34%


$ (3,426)


$ 1,092,336


33%


























 Six Months Ended 


June 30,

Revenues(a)(b)

2013

GAAP


2012

GAAP


%   Change


2013 currency impact


2013 excluding currency impact

 non-GAAP


%   Change

    U.S. Promoted

$    969,726


$    584,938


66%


$        -


$    969,726


66%

    U.S. Neurology & Other

323,371


351,008


-8%


-


323,371


-8%

    Canada/Australia

269,872


260,929


3%


3,532


273,404


5%

Developed Markets

1,562,969


1,196,875


31%


3,532


1,566,501


31%

     Emerging Markets-Central/Eastern Europe

372,543


288,203


29%


(5,681)


366,862


27%

     Emerging Markets-Latin America

170,851


144,288


18%


982


171,833


19%

     Emerging Markets-Southeast Asia/Africa

57,754


46,827


23%


3,691


61,445


31%

Emerging Markets

601,148


479,318


25%


(1,008)


600,140


25%

Total Revenues

$ 2,164,117


$ 1,676,193


29%


$   2,524


$ 2,166,641


29%













(a) Note: Currency effect for constant currency sales is determined by comparing 2013 reported amounts adjusted to exclude currency impact, calculated using 2012 monthly average exchange rates, to the actual 2012 reported amounts. Constant currency sales is not a GAAP-defined measure of revenue growth. Constant currency sales as defined and presented by us may not be comparable to similar measures reported by other companies. 




(b) See footnote (a) to Table 2a.








Valeant Pharmaceuticals International, Inc.


Table 4

Reconciliation of GAAP Cost of Goods Sold to Non-GAAP Cost of Goods Sold - by Segment



For the Three and Six Months Ended June 30, 2013



(In thousands)





4.1

Cost of goods sold (a)







Three Months Ended



June 30,




2013

as reported

GAAP


%

of product sales


2013

 fair value step-up adjustment to inventory and Other non-GAAP    (b)


2013 excluding fair value step-up adjustment to inventory and Other

non-GAAP


%

of product sales


Developed Markets

$   158,346


21%


$          30,428


$       127,918


17%


Emerging Markets

124,837


42%


8,532


116,305


40%














$   283,183


27%


$          38,960


$       244,223


23%















































 Six Months Ended 



June 30,



2013

as reported

GAAP


%

of product sales


2013

 fair value step-up adjustment to inventory and Other non-GAAP    (c)


2013 excluding fair value step-up adjustment to inventory and Other

non-GAAP


%

of product sales


Developed Markets

$   317,758


21%


$          77,332


$       240,426


16%


Emerging Markets

250,329


43%


15,617


234,712


40%














$   568,087


27%


$          92,949


$       475,138


23%
























(a) See footnote (a) to Table 2a.




(b) Developed Markets include $24.5 million of fair value step-up adjustment to inventory and $6.3 million of integration related tech transfer costs offset by PP&E step down of $0.4 million.  Emerging Markets include $2.0 million of fair value step up adjustment to inventory, $4.4M of integration related tech transfer costs, $1.4 million BMS fair value inventory adjustment and $0.7 million of PP&E step up and other.




(c) Developed Markets include $65.6 million of fair value step-up adjustment to inventory and $12.3 million of integration related tech transfer costs offset by PP&E step down of $0.6 million.  Emerging Markets include $4.2 million of fair value step up adjustment to inventory, $5.8M of integration related tech transfer costs, $3.5 million BMS fair value inventory adjustment and $2.1 million of PP&E step up and other.








Valeant Pharmaceuticals International, Inc.

Table 5


Consolidated Balance Sheet and Other Data



(In thousands)




As of


As of




June 30,


December 31,


5.1

Cash

2013


2012









Cash and cash equivalents 

$     2,539,390


$        916,091



Marketable securities 

-


4,410



Total cash and marketable securities

$     2,539,390


$        920,501















Debt












New Term Loan A Facility

$     1,876,228


$     2,083,462



New Term Loan B Facility

1,263,793


1,275,167



New Incremental Term Loan B Facility

972,272


973,988



New Revolving Credit Facility

225,000


-



Senior Notes 

6,451,687


6,448,317



Convertible Notes

209


233,793



Other

4,916


898




10,794,105


11,015,625



Less: Current portion

(346,875)


(480,182)




$   10,447,230


$   10,535,443








5.2

Summary of Cash Flow Statements

Three Months Ended




June 30,




2013


2012



Cash flow provided by (used in):












Net cash provided by operating activities (GAAP)

$        305,028


$        254,602



Restructuring, acquisition-related and other costs(c)

58,039


43,871



Payment of accrued legal settlements

11,728


1,752



Payment of Accreted Interest on Convertible Debt

-


-



Tax Benefit from Stock Options Exercised (a)

11,845


2,882



Cash Settlement of BOD Equity Awards

21,381


-



Working Capital change related to Business Development Activities

21,707


-



Non-Cash adjustments to Income Taxes Payable

-


-



Changes in working capital related to restructuring, acquisition-related and other costs(c)

(6,233)


4,379



Adjusted cash flow from operations (Non-GAAP) (b)

$        423,495


$        307,486















(a) Includes stock option tax benefit which will reduce taxes in future periods.






(b) See footnote (a) to Table 2a.






(c) Total Restructuring, acquisition-related and other costs cash payments of $51,806 are broken down as follows:






Project Type

Amount Paid











Medicis

24,960





Obagi

7,130





Intellectual property migration

5,758





Europe (including Nature Produkt & Lek-Am)

3,679





Manufacturing integration (various deals)

2,511





Ophthalmology (QLT and Eyetech)

1,542





OraPharma

1,447





U.S. restructuring

759





Bausch & Lomb

416





Systems integration (various deals U.S./Canada)

413





Other

3,191











Total

$                  51,806











Expense Type

Amount Paid











Integration related consulting, duplicative labor, transition services, and other

21,408





Severance payments

14,249





Acquisition-related costs paid to 3rd parties

8,636





Facility closure costs, other manufacturing integration, and other

5,303





Stock-based compensation

2,210











Total

$                  51,806


























Valeant Pharmaceuticals International, Inc.










Table 6

Organic Growth - by Segment 











For the Three Months Ended June 30, 2013











(In thousands)





























 For the Three Months Ended June 30, 















 Organic growth 










(a)

(b)




 (b) 


 (b) 


 (1) 

 QTD

2013

 (2)   Acq impact 

 (3)    QTD

Same store


 (4)    QTD

2012 

 (5)    Pro Forma Adj 

 (6)     Pro Forma 2012 


 (7)    Currency impact Same store 

 (8)    Currency impact Acq 


 (9)    Divestitures / Discontinuations (c ) 


 Pro Forma    (1)+(7)+(8)+(9) / (6) 


Same store (3)+(7) / (4)-(9)


















U.S. Promoted

476.8

243.6

233.3


249.5

242.9

492.4


-

-


4.6


-2%


-5%

U.S. Neurology & Other    (d )

162.8

18.8

143.9


142.5

17.9

160.4


-

-


1.9


3%


2%

Canada/Australia     (e)

134.4

15.0

119.4


118.9

15.6

134.5


1.8

0.2


2.5


3%


4%

Developed Markets

774.0

277.4

496.6


510.9

276.4

787.3


1.8

0.2


9.0


0%


-1%

Emerging Markets - Central/Eastern Europe

179.2

21.8

157.5


136.7

22.4

159.0


(4.9)

(0.3)


1.3


10%


13%

Emerging Markets - Latin America

89.1

5.3

83.9


73.4

3.8

77.2


(1.9)

(0.3)


3.4


17%


17%

Emerging Markets - Southeast Asia/Africa

25.7

0.3

25.5


24.9

0.2

25.1


2.1

0.0


-


11%


11%

Emerging Markets

294.1

27.3

266.8


235.0

26.4

261.4


(4.7)

(0.6)


4.7


12%


14%

Total product sales

1,068.1

304.7

763.3


745.9

302.8

1,048.7


(2.8)

(0.4)


13.7


3%


4%




































 Normalized for:    1) Generic impact of Zovirax Ointment 





































 For the Three Months Ended June 30, 















 Organic growth 










(a)

(b)




 (b) 


 (b) 


 (1)     QTD

2013 

 (2)     Acq impact 

 (3)    QTD

Same store 


 (4)     QTD

2012 

 (5)     Pro Forma Adj 

 (6)     Pro Forma 2012 


 (7)   Currency impact Same store 

 (8)    Currency impact Acq 


 (9)    Divestitures / Discontinuations (c ) 


 Pro Forma    (1)+(7)+(8)+(9) / (6) 


Same store (3)+(7) / (4)-(9)


















U.S. Promoted     (f)

472.7

243.6

229.2


224.8

242.9

467.7


-

-


4.6


2%


4%

U.S. Neurology & Other    (d )

162.8

18.8

143.9


142.5

17.9

160.4


-

-


1.9


3%


2%

Canada/Australia     (e)

134.4

15.0

119.4


118.9

15.6

134.5


1.8

0.2


2.5


3%


4%

Developed Markets

769.9

277.4

492.5


486.2

276.4

762.6


1.8

0.2


9.0


2%


4%

Emerging Markets - Central/Eastern Europe

179.2

21.8

157.5


136.7

22.4

159.0


(4.9)

(0.3)


1.3


10%


13%

Emerging Markets - Latin America

89.1

5.3

83.9


73.4

3.8

77.2


(1.9)

(0.3)


3.4


17%


17%

Emerging Markets - Southeast Asia/Africa

25.7

0.3

25.5


24.9

0.2

25.1


2.1

0.0


-


11%


11%

Emerging Markets

294.1

27.3

266.8


235.0

26.4

261.4


(4.7)

(0.6)


4.7


12%


14%

Total product sales

1,064.0

304.7

759.2


721.1

302.8

1,023.9


(2.8)

(0.4)


13.7


5%


7%




































 Normalized for:    1) Generic impact of Zovirax franchise 





































 For the Three Months Ended June 30, 















 Organic growth 










(a)

(b)




 (b) 


 (b) 


 (1)    QTD

2013 

 (2)    Acq impact 

 (3)     QTD

Same store 


 (4)     QTD

2012 

 (5)     Pro Forma Adj 

 (6)     Pro Forma 2012 


 (7)     Currency impact Same store 

 (8)   Currency impact Acq 


 (9)    Divestitures / Discontinuations (c ) 


 Pro Forma    (1)+(7)+(8)+(9) / (6) 


Same store (3)+(7) / (4)-(9)


















U.S. Promoted     (g)

457.2

243.6

213.6


204.0

242.9

446.9


-

-


4.6


3%


7%

U.S. Neurology & Other    (d )

162.8

18.8

143.9


142.5

17.9

160.4


-

-


1.9


3%


2%

Canada/Australia     (e)

134.4

15.0

119.4


118.9

15.6

134.5


1.8

0.2


2.5


3%


4%

Developed Markets

754.3

277.4

476.9


465.4

276.4

741.8


1.8

0.2


9.0


3%


5%

Emerging Markets - Central/Eastern Europe

179.2

21.8

157.5


136.7

22.4

159.0


(4.9)

(0.3)


1.3


10%


13%

Emerging Markets - Latin America

89.1

5.3

83.9


73.4

3.8

77.2


(1.9)

(0.3)


3.4


17%


17%

Emerging Markets - Southeast Asia/Africa

25.7

0.3

25.5


24.9

0.2

25.1


2.1

0.0


-


11%


11%

Emerging Markets

294.1

27.3

266.8


235.0

26.4

261.4


(4.7)

(0.6)


4.7


12%


14%

Total product sales

1,048.4

304.7

743.7


700.3

302.8

1,003.2


(2.8)

(0.4)


13.7


6%


8%


















(a) Note: Currency effect for constant currency sales is determined by comparing 2013 reported amounts adjusted to exclude currency impact, calculated using 2012 monthly average exchange rates, to the actual 2012 reported amounts. Constant currency sales is not a GAAP-defined measure of revenue growth. Constant currency sales as defined and presented by us may not be comparable to similar measures reported by other companies. 


(b) See footnote (a) to Table 2a.
















(c) Includes divestitures, discontinuations and supply interruptions.
















(d) Includes Valeant's attributable portion of revenue from joint ventures (JV) -  $2.1M Q2'13 and $1.1M Q2'12
















(e) Includes Valeant's attributable portion of revenue from joint ventures (JV) -  $2.5M Q2'13 and $1.8M Q2'12.
















(f) Excludes revenue from genericized products of $4.1M Q2'13 and $24.8M Q2'12
















(g) Excludes revenue from genericized products of $19.6M Q2'13 and $45.5M Q2'12








 

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

 

SOURCE Valeant Pharmaceuticals International, Inc.



RELATED LINKS
http://www.valeant.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.